Treatment plan includes neoadjuvant chemotherapy followed by potential interval debulking surgery at UPMC Magee Womens Hospital, UPMC Hillman Cancer Center, UPMC Shadyside Hospital, or UPMC Passavant Hospital
Consented to participate in STUDY19060197: HCC 07-058
Neoadjuvant chemotherapy has not yet been initiated
ECOG Performance Status Scale score of ≤ 2
Ability to provide written informed consent
Ability to understand, speak, and read English. (Many of the study instruments utilized are not readily available in multiple languages. Additionally, site-based study staff, such as exercise physiologists and clinical research coordinators, are not bilingual.)
You may not be if
Evidence in the EHR of an absolute contraindication for exercise (e.g., Heart insufficiency \> NYHA III or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability)
Any other comorbidities or musculoskeletal complications that preclude participation in the exercise programs as deemed by the exercise interventionist
Receiving non-HGSOC related chemotherapy and/or radiotherapy
Active infections, hemorrhages, and cytopenias that could place surgical patients at risk for further adverse events, deemed by the exercise interventionist, physician, and/or nurse
